All In Biotech

Drug Trial Radar · NCT06642909

A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy

A Multicenter, Randomized, Open Label, Cyclosporine Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Zuberitamab Injection (HS006) in Patients With Primary Membranous Nephropathy

Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Nov 13, 2024

Primary completion

Mar 31, 2027

Study completion May 10, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, open label, cyclosporine controlled Phase II trial aimed at evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of Zuberitamab in patients with primary membranous nephropathy, and exploring the Phase III dosing regimen, sample size, and endpoint evaluation time

Conditions

  • Primary Membranous Nephropathy

Interventions

  • Zuberitamab 600mgDrug

    administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks

  • Zuberitamab 1000mgDrug

    administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks

  • cyclosporineDrug

    Initial dose of 3.5 mg/kg/d, oral administration, divided into two doses, taken 12 hours apart (Q12h)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects who achieved overall response (OR) in the urinary protein/creatinine ratio (UPCR) at week 76Time frame: Week 76

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.